Suppr超能文献

人错配修复蛋白对顺铂-DNA加合物的选择性识别。

Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins.

作者信息

Yamada M, O'Regan E, Brown R, Karran P

机构信息

Imperial Cancer Research Fund, Clare Hall Laboratories, South Mimms, Hertfordshire EN6 3LD, UK.

出版信息

Nucleic Acids Res. 1997 Feb 1;25(3):491-6. doi: 10.1093/nar/25.3.491.

Abstract

The antitumor agent cis-diamminedichloroplatinum(II) (cisplatin) introduces cytotoxic DNA damage predominantly in the form of intrastrand crosslinks between adjacent purines. Binding assays using a series of duplex oligonucleotides containing a single 1,2 diguanyl intrastrand crosslink indicate that human cell extracts contain factors that preferentially recognise this type of damage when the complementary strand contains T opposite the 3', and C opposite the 5'guanine in the crosslink. Under the conditions of the band-shift assay used, little binding is observed if the positions of the T and C are reversed in the complementary strand. Similarly, duplexes containing CC or TT opposite the crosslink are recognised relatively poorly. The binding activity is absent from extracts of the colorectal carcinoma cell lines LoVo and DLD-1 in which the hMutSalpha mismatch recognition complex is inactivated by mutation. Extensively purified human hMutSalpha exhibits the same substrate preference and binds to the mismatched platinated DNA at least as well as to an identical unplatinated duplex containing a single G.T mismatch. It is likely, therefore, that human mismatch repair may be triggered by 1,2 diguanyl intrastrand crosslinks that have undergone replicative bypass.

摘要

抗肿瘤药物顺 - 二氯二氨合铂(II)(顺铂)主要以相邻嘌呤之间的链内交联形式引入细胞毒性DNA损伤。使用一系列含有单个1,2 - 二鸟嘌呤链内交联的双链寡核苷酸进行的结合试验表明,当互补链在交联处3'端相对位置含有T,5'端鸟嘌呤相对位置含有C时,人细胞提取物中含有优先识别这种类型损伤的因子。在所使用的凝胶迁移试验条件下,如果互补链中T和C的位置颠倒,则观察到的结合很少。同样,在交联相对位置含有CC或TT的双链体被识别的程度相对较差。在结直肠癌细胞系LoVo和DLD - 1的提取物中不存在结合活性,在这些细胞系中hMutSα错配识别复合物因突变而失活。经过广泛纯化的人hMutSα表现出相同的底物偏好,并且与错配的铂化DNA结合的能力至少与与含有单个G.T错配的相同未铂化双链体一样好。因此,人错配修复很可能由经历复制性绕过的1,2 - 二鸟嘌呤链内交联触发。

相似文献

1
Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins.
Nucleic Acids Res. 1997 Feb 1;25(3):491-6. doi: 10.1093/nar/25.3.491.
3
Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts.
Nucleic Acids Res. 1997 Feb 1;25(3):480-91. doi: 10.1093/nar/25.3.480.
6
MutS recognition of exocyclic DNA adducts that are endogenous products of lipid oxidation.
J Biol Chem. 1999 Sep 17;274(38):27112-8. doi: 10.1074/jbc.274.38.27112.
8
MutS inhibits RecA-mediated strand exchange with platinated DNA substrates.
Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14174-9. doi: 10.1073/pnas.0406104101. Epub 2004 Sep 16.
9
Modulation of MutS ATP-dependent functional activities by DNA containing a cisplatin compound lesion (base damage and mismatch).
J Mol Biol. 2007 May 25;369(1):27-40. doi: 10.1016/j.jmb.2007.02.048. Epub 2007 Feb 22.
10
Separation of mutation avoidance and antirecombination functions in an Escherichia coli mutS mutant.
Nucleic Acids Res. 2005 Feb 24;33(4):1193-200. doi: 10.1093/nar/gki263. Print 2005.

引用本文的文献

2
Replication-Independent ICL Repair: From Chemotherapy to Cell Homeostasis.
J Mol Biol. 2024 Jul 1;436(13):168618. doi: 10.1016/j.jmb.2024.168618. Epub 2024 May 18.
3
Revisiting the Anti-Cancer Toxicity of Clinically Approved Platinating Derivatives.
Int J Mol Sci. 2022 Dec 6;23(23):15410. doi: 10.3390/ijms232315410.
4
Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors.
Cancer Drug Resist. 2019;2(3):580-594. doi: 10.20517/cdr.2019.19. Epub 2019 Sep 19.
6
Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibodies Perspective.
World J Oncol. 2014 Jun;5(3):97-108. doi: 10.14740/wjon830w. Epub 2014 Jun 25.
7
Repair shielding of platinum-DNA lesions in testicular germ cell tumors by high-mobility group box protein 4 imparts cisplatin hypersensitivity.
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):950-955. doi: 10.1073/pnas.1615327114. Epub 2017 Jan 17.
8
DNA Polymerase Beta Germline Variant Confers Cellular Response to Cisplatin Therapy.
Mol Cancer Res. 2017 Mar;15(3):269-280. doi: 10.1158/1541-7786.MCR-16-0227-T. Epub 2017 Jan 10.
9
Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links.
DNA Repair (Amst). 2015 Nov;35:126-36. doi: 10.1016/j.dnarep.2015.10.003. Epub 2015 Oct 23.
10

本文引用的文献

1
Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts.
Nucleic Acids Res. 1997 Feb 1;25(3):480-91. doi: 10.1093/nar/25.3.480.
2
Fork-like DNA templates support bypass replication of lesions that block DNA synthesis on single-stranded templates.
Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13766-9. doi: 10.1073/pnas.93.24.13766.
3
Mismatch repair in replication fidelity, genetic recombination, and cancer biology.
Annu Rev Biochem. 1996;65:101-33. doi: 10.1146/annurev.bi.65.070196.000533.
4
The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin.
Chem Biol. 1996 Jul;3(7):579-89. doi: 10.1016/s1074-5521(96)90149-0.
5
hMutSbeta, a heterodimer of hMSH2 and hMSH3, binds to insertion/deletion loops in DNA.
Curr Biol. 1996 Sep 1;6(9):1181-4. doi: 10.1016/s0960-9822(02)70685-4.
8
Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine.
Science. 1996 Aug 23;273(5278):1109-11. doi: 10.1126/science.273.5278.1109.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验